1.27 USD
▼-0.02-1.55%
盘后 1.29 +1.57%
2026-09-15
市值
$134.01M
市盈率
—
EPS
-1.07
股息率
—
52 周区间
1.25 – 3.54
成交量
1.69M
Beta
2.28
目标价
11.86
52W 低 1.2552W 高 3.54
价格走势
公司简介
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCM...